Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report
Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate can...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2024-01-01
|
| Col·lecció: | Leukemia Research Reports |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2213048924000633 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|